Sun Pharma's Phase IV Study on Dual Release Pantoprazole for GERD Gets CDSCO Panel Acceptance

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-12 08:16 GMT | Update On 2025-08-12 08:16 GMT

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has accepted the results of Sun Pharma's Phase IV clinical trial on Dual Release Gastro-Resistant Pantoprazole 80mg for the treatment of partial or non-responders to standard proton pump inhibitor (PPI) doses in gastroesophageal reflux disease (GERD). The panel noted that the findings will not be used for regulatory approvals.

The trial, titled “Dual Release Gastro-Resistant Pantoprazole 80mg for Treatment of Partial or Non-Responders to Standard Dose of Proton Pump Inhibitor (PPI) in Gastroesophageal Reflux Disease (GERD) – A Prospective pH-Metry/Impedance Controlled Study”, was reviewed at the SEC (Gastroenterology & Hepatology) meeting held on 24 July 2025.

Sun Pharma informed the committee that the study was conducted solely to generate additional data and information, not for regulatory submissions.

Pantoprazole, a proton pump inhibitor, works by binding irreversibly and specifically to the proton pump, reducing gastric acid secretion. It is used to treat erosive esophagitis and other conditions involving excess stomach acid, including GERD.

After detailed deliberation, the SEC recommended: “To accept the result of the Phase IV CT study and same may not be used for regulatory approvals.”

Also Read: Eli Lilly Gets CDSCO Panel Nod for Ixekizumab Safety Label Update

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma's Phase IV Study on Dual Release Pantoprazole for GERD Gets CDSCO Panel Acceptance

Similar News

Not All Combipacks Are New Drugs: CDSCO Defines Approval Rules for Lyophilized Injections

Bombay HC Quashes Maharashtra FDA, CDSCO Stop-Production Orders Against 2 Pharma Firms

Intas Pharma Told to Narrow Margins, Extend Duration in Pembrolizumab Trial Protocol

MSN Lab gets CDSCO panel nod for Phase IV CT of Tofacitinib Oral Solution

Health Ministry Bans 34 Key Antibiotics, Antivirals for Animal Use, See List

CDSCO Panel Recommends Updating Prescribing Information for Sanofi's Vaccine

CDSCO Panel Approves Novo Medi Sciences' Phase III Booster Study of PCV13 Pneumococcal Vaccine in Infants

CDSCO Panel Asks Takeda to Submit Full Phase III Data on Dengue Tetravalent Vaccine